afimkibart vs tulisokibart
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
Shared mechanism: TL1A · full Ulcerative Colitis pipeline
afimkibart
Developed by Roche and partners
NCT04090411 · Phase 2 · completed
This was a randomized, double-blind, placebo-controlled Phase 2 study (N=246) in moderate-to-severe ulcerative colitis, with Week 14 clinical remission on the Mayo score as the primary endpoint. Although remission rates were numerically higher in all afimkibart dose groups (25.5%, 23.3%, 23.9%) than placebo (11.6%), the differences were not statistically significant (one-sided p-values 0.055–0.082; 90% confidence intervals crossed zero), so the primary efficacy comparison was not met. The well-controlled design is real evidence, but because the primary endpoint was missed, the trial does not rise to strong evidence of benefit.
Next expected readout: January 2027 · NCT06589986 (registry estimate)
Reported efficacy
Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14; Induction Period: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Induction Period: Number of Participants With Serious Adverse Events (SAEs) (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Induction Period: Number of Participants With AEs or SAEs Leading to Discontinuation (From initiation of study treatment to either first dose in the chronic period or end of safety follow-up, whichever occurs first. (Approximately 16 weeks plus 12-week safety follow-up, if applicable.)); Chronic Period: Number of Participants With TEAEs (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)); Chronic Period: Number of Participants With SAEs (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)); Chronic Period: Number of Participants With AEs or SAEs Leading to Discontinuation (From first dose of study treatment in the chronic period to end of safety follow-up. (Approximately 40 weeks plus 12-week safety follow-up.)): Induction Period: Percentage of Participants Who Achieved Clinical Remission at Week 14 (At Week 14): Induction Period: Placebo 11.6% (95% CI 5.77-22.88) vs Induction Period: PF-06480605 50 mg 25.5% (95% CI 15.44-37.19) vs Induction Period: PF-06480605 150 mg 23.3% (95% CI 14.98-33.98) vs Induction Period: PF-06480605 450 mg 23.9% (95% CI 16.58-32.06); p=0.0545 (Induction Period: Placebo vs Induction Period: PF-06480605 50 mg), p=0.0823 (Induction Period: Placebo vs Induction Period: PF-06480605 150 mg), p=0.0642 (Induction Period: Placebo vs Induction Period: PF-06480605 450 mg) (missed)
Result source: NCT04090411
tulisokibart
Developed by Merck & Co.
NCT06052059 · Phase 3 · active, not recruiting
First Ph3 induction win for any anti-TL1A; met primary + key secondaries (June 2026).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: December 2037 · NCT06651281 (registry estimate)
Reported efficacy
Clinical remission (MMS) at week 12: ATLAS-UC Study 2 (NCT06052059): tulisokibart met its primary endpoint of clinical remission (Modified Mayo Score) at week 12, plus key secondary endpoints. (met)
Result source: NCT06052059
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | afimkibart | tulisokibart |
|---|---|---|
| Clinical remission (induction) | 23.9% vs 11.6%+12.3 vs placeboNCT040904112 other results
| 26.5% vs 1.5%+25 vs placeboNCT049967971 other result
|
| Clinical remission (maintenance) | —Trial running · NCT06589986 | —Trial running · NCT06052059 |
| Clinical response (induction) | —Trial running · NCT06589986 | 66.2% vs 22.4%+43.8 vs placeboNCT049967971 other result
|
| Endoscopic improvement (induction) | 40.9% vs 18.6%+22.3 vs placeboNCT040904118 other results
| 36.8% vs 6%+30.8 vs placeboNCT049967971 other result
|
| Corticosteroid-free remission (maintenance) | —Trial running · NCT06589986 | —Trial running · NCT06052059 |
Clinical remission (induction)
- afimkibart
- 23.9% vs 11.6%+12.3 vs placeboNCT04090411
2 other results
- 23.3% vs 11.6% NCT04090411
- 25.5% vs 11.6% NCT04090411
- tulisokibart
- 26.5% vs 1.5%+25 vs placeboNCT04996797
1 other result
- 31.6% vs 10.8% NCT04996797
Clinical remission (maintenance)
- afimkibart
- —Trial running · NCT06589986
- tulisokibart
- —Trial running · NCT06052059
Clinical response (induction)
- afimkibart
- —Trial running · NCT06589986
- tulisokibart
- 66.2% vs 22.4%+43.8 vs placeboNCT04996797
1 other result
- 55.3% vs 32.4% NCT04996797
Endoscopic improvement (induction)
- afimkibart
- 40.9% vs 18.6%+22.3 vs placeboNCT04090411
8 other results
- 36% vs 18.6% NCT04090411
- 37.5% vs 18.6% NCT04090411
- 50% vs 18.6% NCT04090411
- 38.3% vs 18.6% NCT04090411
- 37% vs 18.6% NCT04090411
- 39.3% vs 18.6% NCT04090411
- 40.4% vs 18.6% NCT04090411
- 38.1% vs 18.6% NCT04090411
- tulisokibart
- 36.8% vs 6%+30.8 vs placeboNCT04996797
1 other result
- 36.8% vs 18.9% NCT04996797
Corticosteroid-free remission (maintenance)
- afimkibart
- —Trial running · NCT06589986
- tulisokibart
- —Trial running · NCT06052059
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. afimkibart: 4 of 4 rows · tulisokibart: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | afimkibart | tulisokibart |
|---|---|---|
| Dropout rate | 8.7%450 mga NCT04090411 · Phase 2 show 9 more results—450 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 —450 mg (Induction) to 450 mg (Chronic) NCT04090411 · Phase 2 —450 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 6.5%150 mg NCT04090411 · Phase 2 —150 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 —150 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 2.1%50 mg NCT04090411 · Phase 2 —50 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 2%500 mg IV NCT02840721 · Phase 2 · registry result, not featured evidence | —All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more resultn/a: no completion milestoneCohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Discontinued due to AEs | 1.1%450 mga NCT04090411 · Phase 2 show 9 more results—450 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 —450 mg (Induction) to 450 mg (Chronic) NCT04090411 · Phase 2 —450 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 1.6%150 mg NCT04090411 · Phase 2 —150 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 —150 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 2.1%50 mg NCT04090411 · Phase 2 —50 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 2%500 mg IV NCT02840721 · Phase 2 · registry result, not featured evidence | —All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more result0%Cohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Serious AEs | 4.4%450 mga NCT04090411 · Phase 2 show 9 more results3.8%450 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 13.8%450 mg (Induction) to 450 mg (Chronic) NCT04090411 · Phase 2 7.7%450 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 1.6%150 mg NCT04090411 · Phase 2 0%150 mg (Induction) to 150 mg (Chronic) NCT04090411 · Phase 2 3.7%150 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 6.4%50 mg NCT04090411 · Phase 2 10.9%50 mg (Induction) to 50 mg (Chronic) NCT04090411 · Phase 2 6%500 mg IV NCT02840721 · Phase 2 · registry result, not featured evidence | 1.1%All Cohorts (Cohort 1 & Cohort 2) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 show 1 more result—Cohort 1 Tulisokibart NCT04996797 · Phase 2 · monotherapy · Ulcerative Colitis · phase 2 |
| Most frequent reported AEs | 450 mga headache 9.9% (placebo 2.2%) fatigue 5.5% (placebo 0%) pyrexia 5.5% (placebo 2.2%) NCT04090411 · Phase 2 show 9 more results450 mg (Induction) to 150 mg (Chronic) anaemia 11.5% (placebo 8.9%) colitis ulcerative 11.5% (placebo 0%) sars-cov-2 test positive 11.5% (placebo 0%) NCT04090411 · Phase 2 450 mg (Induction) to 450 mg (Chronic) blood creatine phosphokinase increased 10.3% (placebo 4.4%) anaemia 6.9% (placebo 8.9%) covid-19 6.9% (placebo 0%) NCT04090411 · Phase 2 450 mg (Induction) to 50 mg (Chronic) colitis ulcerative 23.1% (placebo 0%) sars-cov-2 test positive 15.4% (placebo 0%) anaemia 11.5% (placebo 8.9%) NCT04090411 · Phase 2 150 mg anaemia 8.1% (placebo 8.9%) injection site reaction 4.8% (placebo 2.2%) headache 3.2% (placebo 2.2%) NCT04090411 · Phase 2 150 mg (Induction) to 150 mg (Chronic) nausea 10% (placebo 2.2%) oropharyngeal pain 10% (placebo 2.2%) sars-cov-2 test positive 10% (placebo 0%) NCT04090411 · Phase 2 150 mg (Induction) to 50 mg (Chronic) sars-cov-2 test positive 18.5% (placebo 0%) colitis ulcerative 14.8% (placebo 0%) injection site reaction 11.1% (placebo 2.2%) NCT04090411 · Phase 2 50 mg nausea 6.4% (placebo 2.2%) urinary tract infection 6.4% (placebo 0%) anaemia 4.3% (placebo 8.9%) NCT04090411 · Phase 2 50 mg (Induction) to 50 mg (Chronic) colitis ulcerative 17.4% (placebo 0%) anaemia 8.7% (placebo 8.9%) blood creatine phosphokinase increased 6.5% (placebo 4.4%) NCT04090411 · Phase 2 500 mg IV arthralgia 12% colitis ulcerative 10% abdominal pain 6% NCT02840721 · Phase 2 · registry result, not featured evidence | covid-19 5.6% (placebo 4.5%) NCT04996797 · Phase 2 · Ulcerative Colitis · phase 2 |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
afimkibart
show 2 more results
show 8 more results
show 8 more results
show 8 more results
show 8 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
show 5 more results
+ 2 further endpoints in the CSV export.
tulisokibart
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: afimkibart's landscape · tulisokibart's landscape